CHAPTER 11

Virus-Like Particles as a Vaccine Delivery System:
Myths and Facts

Polly Roy* and Rob Noad

Abstract

Vaccines against viral disease have traditionally relied on attenuated virus strains or inactivation of infectious virus. Subunit vaccines based on viral proteins expressed in heterologous systems have been effective for some pathogens, but have often suffered from poor immunogenicity due to incorrect protein folding or modification. In this chapter we focus on a specific class of viral subunit vaccine that mimics the overall structure of virus particles and thus preserves the native antigenic conformation of the immunogenic proteins. These virus-like particles (VLPs) have been produced for a wide range of taxonomically and structurally distinct viruses, and have unique advantages in terms of safety and immunogenicity over previous approaches. With new VLP vaccines for papillomavirus beginning to reach the market place we argue that this technology has now ‘come-of-age’ and must be considered a viable vaccine strategy.

Introduction

There are many infectious viruses that remain major threats to public health (see Table 1). Where an effective vaccine exists, vaccination is usually the most cost-effective long-term protection against disease and spread for most viruses. The principle of vaccination is to generate sufficient immunity to protect from infectious disease. Thus the vaccine stimulates the body’s natural defenses against disease through use of a benign ‘decoy’ that mimics the virulent pathogen. The more similar a vaccine is to the natural disease, the better the immune response to the pathogen on subsequent exposure. In general, resistance to virus infection depends on the development of an immune response to antigens present on the surface of virions or virus-infected cells. Therefore identification of protective antigens is the first step in the development of effective viral vaccines.

Currently many successful viral vaccines have been developed and are in use. These vaccines are predominantly based on live attenuated or inactivated viruses. The live attenuated vaccines such as measles, mumps, rubella, oral polio, smallpox, varicella and yellow fever are a weakened form of the “wild” viruses. These attenuated virus vaccines rely on limited replication of the virus in the host following vaccination. Immune responses induced are similar to those from natural infections and often these vaccines are effective after a single dose. However, such vaccines may cause severe reactions in some patients, which are often the result of the limited replication of the attenuated virus following vaccination. In contrast to attenuated live virus vaccines, inactivated (or killed) vaccines can not replicate, as their genetic material or overall structure are purposefully destroyed. These vaccines are safer than live vaccines but generally not as effective, requiring 3-5

*Corresponding Author: Polly Roy—London School of Hygiene and Tropical Medicine, Keppel St., London, WC1E 7HT, U.K. Email: polly.roy@lshtm.ac.uk

Pharmaceutical Biotechnology, edited by Carlos A. Guzmán and Giora Z. Feuerstein. ©2009 Landes Bioscience and Springer Science+Business Media.
Table 1. Viruses that are major health threats

| Virus                  | Disease                                      |
|------------------------|----------------------------------------------|
| HIV                    | AIDS                                         |
| RSV                    | Respiratory Infection                        |
| Hepatitis B            | Liver Cancer                                 |
| Hepatitis C            | Cirrhosis/Cancer                             |
| Epstein Barr Virus     | Lymphomas, Nasopharyngeal carcinoma          |
| HPV                    | Cervical Cancer                              |
| Measles                | Pneumonia (infants)                          |
| Influenza              | Pneumonia                                    |

Abbreviations: HIV human immunodeficiency virus, RSV rous sarcoma virus, HPV human papillomavirus.

doses as antibody titer falls over time. They lack the self-boosting qualities of live attenuated vaccines but are safer in the sense that the inherent dangers associated with virus replication are avoided. These vaccines are made as whole cell vaccines (such as Influenza, polio, rabies and hepatitis A) or as fractional or subunit vaccines such as hepatitis B. Subunit vaccines are based on the delivery of only a limited number of viral proteins, often the major protein in the capsid or envelope that is sufficient to confer protective immunity. These vaccines are an incremental step safer than inactivated vaccines because subunit vaccines can be prepared independent to the culture of replicating virus. Indeed, any remaining possibility of incomplete inactivation or batch to batch variation in the safety of the vaccine is eliminated. However, subunit vaccines have traditionally suffered from one important drawback; often single proteins when expressed and purified in the absence of other viral components are less immunogenic than those that are incorporated into infectious virus. This is probably because a proportion of this protein is present in a misfolded conformation relative to the native protein. Thus, more doses with higher amounts of antigen are required to achieve the same level of protection.

A major advance in subunit immunogen production has been assembly of proteins as virus-like particles (VLPs) using protein expression technology in yeast, insect or mammalian cells. VLPs are a highly effective type of subunit vaccines that mimic the overall structure of virus particles without any requirement that they contain infectious genetic material. Indeed, many VLPs lack the DNA or RNA genome of the virus altogether, but have the authentic conformation of viral capsid proteins seen with attenuated virus vaccines, without any of the risks associated with virus replication or inactivation.

VLP preparations are all based on the observation that expression of the capsid proteins of many viruses leads to the spontaneous assembly of particles that are structurally similar to authentic virus.\(^\text{1,4}\) In practical terms, the fact that VLPs mimic the structure of virus particles usually means that VLPs should elicit strong humoral response and that lower doses of antigen relative to subunit vaccines are sufficient to elicit similar protective response. In addition to their ability to stimulate B cell mediated immune responses, VLPs have also been demonstrated to be highly effective at stimulating CD4 proliferative and = (CTL) responses.\(^\text{5,7}\) This feature of VLP vaccines is likely to be a major contribution to their effectiveness in the field. It is also becoming increasingly clear that precise prime-boost strategies can be important to how effective vaccination is as a strategy to control disease. Therefore, the addition of VLP to the 'arsenal' of vaccine strategies for any disease extends the type of prime-boost regime that can be employed.

To date, VLPs have been produced for many different viruses that infect humans and other animals (see Table 2 and review).\(^\text{8}\) One of the most striking features of this group is that it is extremely diverse in terms of the structure of the individual viruses. It includes viruses that have a single capsid protein, multiple capsid proteins and those with and without lipid envelopes. Clearly
Table 2  Baculovirus derived VLPs that have been tested as vaccines

| VLP                          | Family                  | Proteins Expressed | Vaccine Tested In                  | VLP Refs.  |
|------------------------------|-------------------------|---------------------|------------------------------------|------------|
| Papillomavirus, Norwalk and Norwalk-like viruses, Feline calcivirus | Papillomaviridae, Calciviridae | 1                   | Humans (licensed)                   | 10,11,15-20,73 |
| Hepatitis E virus            | Hepeviridae             | 1                   | Mice, cats, humans (Phase I)       | 26,27,74-78 |
| Porcine parvovirus, mink enteritis parvovirus, Canine parvovirus, B19, adeno-associated virus | Paroviridae             | 1                   | Mice, cynomologous monkeys          | 28-30      |
| Chicken anemia virus, Porcine circovirus | Circoviridae           | 1, 2 (chicken anaemia virus) | Chickens                           | 82-85      |
| SV40, JC virus, murine polyomavirus | Polyomaviridae         | 1                   | Mice, rabbits (in vitro)            | 32,86,87   |
| Polio virus                  | Picornaviridae, Reoviridae | 1 (polyprotein)   | -                                  | 88         |
| Rotavirus                    | Picornaviridae, Reoviridae | 4 (bluetongue)    | Sheep (bluetongue)                  | 4,35,42-49,89 |
| Hepatitis C Virus            | Flaviviridae            | 3                   | Mice, baboons                       | 7,51,53    |
| HIV, SIV, FIV, Visna virus, FeLV, BIV, Rous Sarcoma virus | Retroviridae            | 2                   | Mice, guinea pigs                   | 2,3,50,90-96 |
| Newcastle Disease Virus      | Paramyxoviridae         | 1                   | Chickens                           | 97         |
| SARS Coronavirus             | Coronavirus             | 3                   | Mice (in vitro)                     | 54         |
| Hantaan virus                | Bunyaviridae            | 3                   | Mice                               | 98         |
| Influenza A virus            | Orthomyxovirida         | 2-4                 | Mice                               | 52,60,61   |
| Infectious Bursal Disease virus | Birnaviridae          | 1                   | Chickens                           | 34,52,99,100 |

Abbreviations: BTV Bluetongue virus, HIV Human immunodeficiency virus, SIV simian immunodeficiency virus, FIV feline immunodeficiency virus, FeLV feline leukemia virus, SV40 simian virus 40, rota rotavirus.

not all of the VLPs that are generated to date are appropriate vaccine targets, some VLPs have been generated to facilitate in fundamental understanding of virus assembly process, morphogenesis or architecture of viruses. However, an important point remains that the structure of the target virion is not limiting to the success of VLP production. Although various expression systems have been employed for VLP production, this chapter will mainly focus on insect cell culture produced VLPs that are being developed as candidate vaccines. The rationale behind this is that among all expression systems, insect cells, together with baculovirus expressing system, appear to be one of the most promising for VLP technology for development of viral vaccines (Fig. 1).
Figure 1. Key stages of intracellular assembly of VLPs using the baculovirus system. a) Baculovirus acts as a vehicle to efficiently deliver DNA, encoding recombinant proteins, to the nucleus of insect cells. b) Viral DNA is uncoated and replicates in the nucleus. c) Recombinant protein expression is driven by strong very-late viral promoters. d) Viral mRNA is used for the synthesis of recombinant proteins. e) VLPs are assembled by the interaction of proteins within the cytoplasm.

Insect Cells and Baculovirus Expression System as Preferred System for VLP Production

As stated above, a variety of protein expression systems are available to express recombinant proteins and particles. However certain criteria for generation of VLPs as prophylactic vaccines, particularly for human viral infection, must be considered. In order for a VLP to be a realistic vaccine candidate, it needs to be produced in a safe expression system that is easy to scale up to large-scale production. Table 2 shows baculovirus expressed/insect cell produced VLPs that have been demonstrated to be highly immunogenic and potential vaccine candidates. This insect cell-based protein production system has many advantages for VLP production. Firstly, extremely large amounts of correctly folded recombinant proteins can be produced in high-density cell-culture conditions in eukaryotic cells. Secondly, baculovirus expression systems have been developed for expression of multiple foreign proteins simultaneously from a single recombinant virus facilitating capsid assembly in each infected cell. Thirdly, as the insect cells that are used for vaccine production can be cultured without the need for mammalian cell derived supplements, the risks of coculture of opportunistic pathogens is minimized. Fourthly, the baculovirus used for recombinant protein expression has a narrow host range that includes only a few species of Lepidoptera and therefore represents no threat to vaccinated individuals. Finally the baculovirus system is amenable to scale-up for large scale vaccine production.
VLPs Produced for Structurally Simple Non-Enveloped Viruses

For a number of nonenveloped viruses viral capsids are formed by only one or two major proteins and thus are relatively easy to manipulate for generation of VLPs by heterologous expression systems. Examples of these are the VLPs formed by the expression of the major capsid protein of Papillomaviruses, Parvoviruses, Caliciviruses, Circoviruses, Polyomaviruses and Hepatitis E virus (Table 2). All of these viruses are nonenveloped and have a single, virally encoded protein that forms the major structural component of the virion. Papilloma virus VLPs are among the most completely studied of this collection of VLPs and are at the most advanced stage with respect to production of a useful vaccine. VLP of Papilloma viruses are formed from the over expression of the major capsid protein L1.10-12 These particles are highly immunogenic and are able to stimulate both humoral and cell mediated immune responses.13-15 Human Papillomavirus (HPV) is the leading cause of cervical cancer. Globally, approximately 70% of all cervical cancer cases are associated with two serotypes of HPV, HPV-16 and HPV-18. VLPs produced in insect cells have been used successfully for Phase I and II human clinical trials in large numbers and were shown to be highly efficacious.15-19 Moreover, GlaxoSmithKline’s cervical cancer vaccine candidate (Cervarix™) targeting HPV 16/18 is currently undergoing Phase III clinical trials involving more than 30,000 women worldwide. In this Phase III randomized, double-blinded trial conducted in multiple centres in Denmark, Estonia, Finland, Greece, the Netherlands and the Russian Federation. All vaccinees received the HPV VLPs (HPV-16/18 AS04) as follows: 158 10-14 years old healthy girls and 458 15-25 years old young women received the candidate VLP vaccine according to a 0, 1, 6 month schedule and anti-HPV antibody titers were assessed. At month seven 100 per cent seropositivity was achieved in both groups for HPV 16 and 18 although average antibody titers for both HPV types were at least two-fold higher in 10-14 year-old girls. The vaccine was tolerated by all patients and no vaccine related serious adverse effects were detected. Further, the follow-up study clearly demonstrated the sustained efficacy of HPV-16/18 VLPs up to 4.5 years.19,20 In conclusion, the bivalent HPV vaccine is highly immunogenic and safe and induces a high degree of protection against HPV-16 and HPV-18 infection and associated cervical lesions.

These studies are not only an important demonstration of the effectiveness of HPV VLP vaccine, and that multi-serotype VLPs are effective, but also highlight the fact that insect cell produced VLPs are a realistic alternative as human vaccines against viral disease. It should also be mentioned at this point that a tetravalent (HPV-6/11/16/18) VLP vaccine, Gardasil™ (Merk), produced in yeast cells was approved by FDA in June 2006 for use in women aged 9-26.

VLP vaccines for various diseases caused by parvovirus infections are also at an advanced stage although as yet none have undergone such large scale trials as those reported for HPV. Synthesis of major structural proteins VP2 of canine parvovirus (CPV) and porcine parvovirus (PPV) led to assembly of VLPs in insect cells.21,22 Vaccination trials of CPV VLPs in dogs and PPV VLPs in pigs were highly encouraging.21,22 In one efficacy assay dogs that received as little as or 10 µg or 25 µg of CPV VLP were completely protected from virus infection when challenged with virulent virus. Furthermore a single subcutaneous dose of 3 µg same CPV VLP with 50 µg ISCOM adjuvant was able to protect mink against challenge with the anti-genically similar virus, mink enteritis virus (MEV).21 Similarly it has been reported recently that a single immunization with 0.7 µg of PPV (porcine strain) VLPs yielded complete protection in targeted animals against infectious PPV strains.23 Indeed microgram doses of VLPs in gilts were not only highly immunogenic, but were also very efficient in preventing trans-placental virus transmission and significantly reduced the number of reproductive failures. In addition, the feasibility of safe large-scale production of the porcine parvovirus VLP vaccine has been established complying with the European Pharmacopoeia requirements.24

Calicivirus studies have relied heavily on the production of proteins in heterologous systems mainly due to the fact that it is not yet possible to grow the virus in cell culture. Thus, VLP to Norwalk-like viruses have been extremely useful as sources of diagnostic antigen to monitor disease outbreaks. Norwalk virus VLP have also been shown to be effective at stimulating IgG, IgA and humoral responses in mice.24,25 Preliminary Phase I trials in humans to test the safety and
immunogenicity of insect cell expressed Norwalk virus VLPs has confirmed that they are both safe and effectively stimulate IgG and IgA responses.\textsuperscript{26,27} VLPs for Hepatitis E have been assembled using a truncated form of the virus capsid protein.\textsuperscript{28} In immunization studies in mice these VLPs were able to induce systemic and mucosal immune responses following oral administration.\textsuperscript{28,29} Furthermore, oral administration of the Hepatitis E VLPs to cynomolgous monkeys induced IgM, IgA and IgG responses and was sufficient to protect against infection and disease on challenge with virus.\textsuperscript{30} Thus there is clear potential for the application of these VLPs as a vaccine for hepatitis E.

VLP preparations to Circoviruses and Polyoma virus are at a less advanced stage. VLP formation has been reported for Circovirus but as yet no serious attempt has been made at vaccine production. Vaccination of rabbits with VLPs for human JC virus in the presence of adjuvant allowed production of a hyperimmune serum that effectively neutralized infectious virus preparations.\textsuperscript{31} However, in the absence of adjuvant there was no response. This pattern of response is unusual for VLPs in general, which often stimulate strong immune responses even in the absence of adjuvant. Indeed, VLPs of murine polyoma virus were able to stimulate a strong immune response in the absence of adjuvant when administered as a single 610 ng dose.\textsuperscript{32} Intriguingly, these particles appear to be particularly stable with no alteration of particle morphology or reduction in immunogenicity even after 9 weeks storage at room temperature.\textsuperscript{32}

\textbf{VLPs of Structurally Complex Viral Capsids with Multiple Protein Layers}

Viral particles that contain multiple interacting capsid proteins present more of a technical challenge than those that are formed by one or two major capsid proteins. Particularly, it is far more difficult if the assembling proteins of capsids are encoded by multiple discrete mRNAs, but not processed from a single polyprotein as in the case of picornaviruses. This is due the fact that for efficient assembly of a VLP the interacting capsid proteins must be expressed in the vicinity to each other, in other words in the same cell. Assembly of VLPs by processing of polyproteins have been achieved both for poliovirus\textsuperscript{33} and for Infectious Bursal disease virus\textsuperscript{34} using the baculovirus expression system. More complex assembly of multilayered, multiprotein VLPs have also been efficiently produced for the members of the \textit{Reoviridae}. These viruses have capsids made up of concentric layers of different capsid proteins. Co-expression in insect cells of 2-4 of these capsid proteins, depending on the virus and the particle made, has allowed the production of VLP that are empty of the segmented dsRNA viral genome, but are otherwise indistinguishable from authentic viral particles.\textsuperscript{35} The first member of the \textit{Reoviridae} for which VLPs were described is Bluetongue virus (BTV), an insect transmitted animal virus. This remains the system in this family for which the largest variety of different VLPs and recombinant single antigen subunit immunogens made by baculovirus expression systems has been tested. In addition, the requirement for efficient co-expression of viral capsid protein in the same insect cell in this system has resulted in the development of baculovirus multigene expression vectors.\textsuperscript{36,37} We will focus on this system in some detail as it highlights both the effectiveness of VLP vaccines and some of the technological advances that have been made for the production of VLP with complex architecture.

Bluetongue disease affects mainly sheep and cattle and is classified as an emerging disease in Europe.\textsuperscript{38} The disease is caused by bluetongue virus, BTV, which has a multi-layered icosahedral structure formed by nonequimolar amounts of seven viral proteins (VP1-VP7). Three of these structural proteins (VP1, VP4, VP6) are dispensable for the formation of VLPs as they play only an enzymatic role in the virus transcription machinery.\textsuperscript{38} The remaining four structural proteins (VP2, VP5, VP3 and VP7) are organised in two capsids. The inner capsid acts as a scaffold for the assembly of outer capsid that is responsible for cell entry and hence contains the major candidate for virus neutralisation.\textsuperscript{38}

Expression of all four major structural proteins of BTV was achieved by constructing a baculovirus that simultaneously expressed all four proteins.\textsuperscript{37} The advantage of this approach over co-infection with several baculoviruses each expressing a single protein is that equivalent conditions are achieved in all infected cells. Thus assembly of VLP is more efficient as expression
Virus-Like Particles as a Vaccine Delivery System

Figure 2. Summary of production and testing of VLPs for Bluetongue virus. A) Left, cartoon showing the multi-layered structure of BTV VLPs. Right, electron micrograph of negatively stained BTV VLPs. B) Summary of neutralizing antibody response to VLP vaccination in Merino sheep. Sheep were vaccinated with two doses of VLPs with dose ranging from 10 µg to 200 µg as indicated. Neutralising antibody titre was followed for 117 days, at which point the sheep were challenged with virulent BTV. C) Table showing clinical reaction index (CRI) and length of Viraemia in sheep vaccinated with various doses of VLP and control. No signs of bluetongue disease or viraemia were detected in any of the VLP vaccinated animals.

is controlled at the level of the cell, rather than the level of the culture as is the case with mixed infections. BTV VLPs (Fig. 2) are structurally indistinguishable from virus particles but lack the segmented, double-stranded (ds) RNA virus genome normally present in infectious virus.98

Antibodies raised to purified BTV VLPs gave high levels of neutralizing antibodies against the homologous BTV serotype.1 In subsequent clinical trials 1 year-old Merino sheep were vaccinated with various amounts (10-200 µg) of VLPs for BTV serotype 10. All vaccinated animals developed demonstrable neutralizing antibodies99,100 and when challenged with virulent virus after four months of vaccination were completely protected from disease. In contrast, unvaccinated control animals developed typical BT clinical symptoms. Even at doses as low as 10 µg VLP was sufficient to protect animals from any signs of disease. Further efficacy tests were performed where VLPs from two different serotypes were combined to vaccinate the same animal. In these animals VLPs vaccination provided complete protection against the two vaccine serotypes and also partial
protection from challenge with related nonvaccine serotypes. The protective efficacy of vaccination in these trials extended over a long (14 month) period. This observation raises the possibility that a broad spectrum vaccine against all 24 BTV serotypes is a possibility by combining VLPs from a relatively small number of serotypes.

The BTV system also demonstrates the efficiency of VLP vaccines relative to immunization with subunit vaccines based on dissociated antigens or unassembled recombinant antigens. In addition the assembled VLPs the two components of the BTV outer capsid, VP2 and VP5, were also prepared and tested in vaccine studies. While 100 μg VP2, the major serotype determining antigen, was only partially protective for a short duration (75 days) against virulent virus challenge, 50 μg of VP2 combined with 25 μg VP5 was protective. In contrast, 10 μg VLPs (containing only 1-2 μg VP2) afforded a better level of protection for a much longer duration. These studies demonstrate that assembly of antigens into VLPs results in a more effective immunogen than delivery of separately isolated proteins.

In addition to BTV, VLP have also been produced for rotavirus, another member of the Reoviridae. Intriguingly, VLPs formed from the two inner structural proteins alone of the rotavirus capsid have been shown to be effective immunogens in animal models. Indeed in mice even intrarectal immunisation which induces a local mucosal response is sufficient for protection from rotavirus infection. The data from these immunogenicity experiments are encouraging and it is possible rotavirus VLP may provide a viable alternative to the live virus vaccine for rotavirus.

**VLPs from Viruses with Lipid Envelopes**

Many pathogenic viruses such as Influenza, HIV and Hepatitis C are surrounded by an envelope, a membrane that consists of a lipid bilayer derived from the host cell, inserted with virus glycoprotein spikes. These proteins are the targets of neutralizing antibodies and are essential components of vaccine. Due to the inherent properties of lipid envelope, assembly of VLPs in insect cells for these viruses is a different type of technical challenge to those produced for viruses with multiple capsids. Nevertheless, efficient formation of VLPs of a number of enveloped viruses in insect cells has been reported. For example, VLPs of Hepatitis C virus, several retroviruses, SARS Coronavirus and influenza A have demonstrated correct assembly of the the lipid envelope with the glycoproteins inserted. Indeed, for retroviruses, it has been possible to produce hybrid VLPs that contain the gag capsid protein from one virus (SIV) and the envelope protein from another (HIV) in insect cells. Although none of the retrovirus derived VLPs are yet at the stage that they are being used in clinical vaccine trials, initial experiments in animal models are promising.

VLPs for SARS Coronavirus as a basis for vaccination were produced rapidly following the SARS outbreak in 2002-2003. However the control of SARS Coronavirus by epidemiological measures, continued lack of re-emergence of the virus, and difficulties working directly with the virus have severely limited the development of SARS VLPs as vaccine. Despite this, anti-serum raised in mice against insect cell derived SARS VLPs were able to neutralize a retrovirus pseudotyped with the SARS S protein (Fig. 3).

The Hepatitis C VLPs (Fig. 1) have been tested in mice and baboons and shown to be effective at stimulating both cellular and humoral immune responses. In one experiment, 6-8 week old female BALB/c mice were immunized intramuscularly three times, at three week intervals with 20 μg insect cell derived HCV VLP, produced by co-expressing HCV coreE1-E2. Because of the lack of a suitable animal model for HCV infections a recombinant vaccinia virus expressing HCV structural proteins (vvHCV.S) was used as a model system. Vaccinated mice were challenged three days after the final immunization with vvHCV.S and then five days later the ovaries of infected mice were harvested and the vaccinia virus titre determined. Five out of seven vaccinated animals had no detectable vaccinia virus in the ovaries at this point. The remaining two animals had five logs lower vaccinia titres compared to control mice. In addition, this study was able to demonstrate that the VLPs efficacy was based largely on its stimulation of CD4+ and CD8+ T-cell responses. A further study in baboons has demonstrated that the VLPs are well tolerated and can stimulate broad and long-lasting HCV targeted immune responses.
Mouse serumaamples

Virus-LikeParticlesasa VaccineDeliverySystem

Figure 3. Summary of production and testing of VLPs to SARS coronavirus. A) Left, cartoon and right, electron micrograph of VLPs produced by co-expression of E, M and S proteins of SARS coronavirus. These VLPs were used to raise anti-sera in mice and the ability of these anti-sera to protect against infection with a SARS S protein pseudotyped lentivirus were assessed. B) IC90 neutralising antibody dilution for SARS S pseudotyped lentivirus, using sera from 3 mice immunized with SARS VLP, rotavirus VLP and serum obtained from a SARS convalescent patient.

To date, the most structurally complicated enveloped virus particle that has been used to generate VLP is influenza. VLPs for Influenza A H9N2 and H3N2 have been produced by other groups. These studies have shown that expression of the major structural protein M1 alone is sufficient result in the budding of virus-like vesicles from insect cells. Also, co-expression of M1 with M2, HA and NA leads to the assembly of influenza VLP and M1-HA and M1-HA-NA VLPs confer protection from lethal challenge with the same type influenza A in mice. VLP production was also successfully achieved by co-expressing HA, NA, M1 and M2 from influenza virus A/Udorn/72 (H3N2) using a single recombinant baculovirus. To date none of these influenza VLP have been tested in humans. However the potential that HA and NA could be incorporated directly into these VLP from circulating influenza strains without passage in tissue culture has particular advantage for the control of rapidly changing influenza A virus.

Future and Alternative Directions

In addition to the use of VLPs as direct immunogens, the efficiency with which they stimulate cellular and humoral responses has made them prime candidates as carrier molecules for the
delivery of epitopes, DNA and small molecules targeting other diseases. This has been facilitated by the excellent structural information that is often available for virus particles allowing rational design of vaccines where epitopes are exposed on the surface of the VLP. Many of the VLPs that have been developed as vaccines in their own right have also been tested as delivery systems for other molecules. It is not possible here to provide a full account of this approach, as the literature on delivery and display using VLPs is at least as large as that on VLP production for direct immunization (for review see ref. 62). However it is necessary at least to introduce this important area of VLP-based vaccine development. The use of VLPs as carrier molecules for epitopes for other diseases is not limited to those VLPs that are formed from the capsids of economically significant viruses. The reason that many VLPs make excellent carrier molecules for the delivery of epitopes in vaccines is most likely because the particulate VLP structure is readily taken up into antigen presenting cells and thus is able to prime long lasting CTL responses in addition to antibody responses. Certainly accumulated evidence on VLP vaccines suggests that they are efficient at stimulating both cellular and humoral immune responses. Notable work has been done in this area with both the hepatitis B core particles, human papillomavirus VLPs and parvovirus VLPs displaying T-cell specific epitopes from another protein on their capsid. These studies demonstrate that like bacterial epitope display systems VLPs are efficient stimulators of MHC class I and class II responses. Thus VLPs have great potential as epitope display systems for other diseases. The only major drawback for this approach is that the requirement of the capsid protein to assemble often constrains the size of the foreign sequence that can be tethered to the VLP. One approach that may be of use to overcome this constraint would be to link foreign protein sequences to capsid proteins in such a way that they extend the N or C termini of the protein and extend either inside or outside to particle. Of course, this is only suitable where one or both termini of the protein are exposed on the inside or outside face of the capsid. So far, there are no VLP that we are aware of that have fully exploited the potential of this approach but it has been successfully employed for other protein-based particulate structures that are similar to VLPs in their stimulation of B-cell and T-cell responses and requirement for complex protein-protein interactions for particle assembly.

Perspectives: Myths and Facts

Despite the accumulated evidence of the potential of VLPs as potent immunogens for many viral systems that we have discussed, there remains some resistance to the VLP approach as a general vaccination strategy for diseases caused by viruses. In part this is due to some high profile disappointing results for VLP vaccines in the early stages of development, for example an ineffective early vaccine for HIV based on Ty VLPs. This example raises a point of caution for VLP vaccine designers. In general, VLPs stimulate efficient cellular and humoral immune responses but, as with any vaccine, they rely on the long term host response to be effective. VLPs designed to work in immunocompromised individuals need to overcome the same challenges to efficient immune response as any other vaccine approach. The notion that VLPs are ineffective vaccines is clearly a myth that is exploded by the imminent release of two new VLP-based HPV vaccines. Indeed, the accumulated data from the field suggests that VLPs are more effective than many other types of subunit vaccines, because they are more conformationally authentic and are safer than many live virus preparations because they are usually free of viral genetic material. VLP production does not appear to be limited to any one type of virus or virus family, nor is it significantly limited by the complexity of the virus particle.

The use of insect cells as a protein expression system offers exciting opportunities for the synthesis of conformationally authentic VLPs that are formed from the intracellular assembly of multiple proteins expressed in the same cell. The advantage of this system over others used for protein expression is its capacity for industrial scale synthesis of large and multiple proteins and the fact that insect cells are the natural replication reservoir for many pathogenic viruses. Thus the basic cellular machinery that normally processes the infectious form of the virus is present within the expression system and available to produce authentic VLPs.
References

1. Miyanohara A, Imamura T, Araki M et al. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J Virol 1986; 59(1):176-80.

2. Delchambre M, Gheysen D, Thines D et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J 1989; 8(9):2653-60.

3. Gheysen D, Jacobs E, de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989; 59(1):103-12.

4. French TJ, Marshall JJ, Roy P. Assembly of double-shelled, virus-like particles of bluetongue virus by the simultaneous expression of four structural proteins. J Virol 1990; 64(12):5695-700.

5. Schirmbeck R, Bohm W, Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 1996; 39(1-2):111-9.

6. Paliard X, Liu Y, Wagner R et al. Priming of strong, broad and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T-cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000; 16(3):273-82.

7. Murata K, Lechmann M, Qiao M et al. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 2003; 100(11):6753-8.

8. Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol 2003; 11(9):438-44.

9. Maranga L, Rueda P, Antonis AF et al. Large scale production and downstream processing of a recombinant porcine parvovirus vaccine. Appl Microbiol Biotechnol 2002; 59(1):45-50.

10. Zhou J, Sun XY, Stenzel DJ et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991; 185(1):251-7.

11. Kirnbauer R, Booy F, Cheng N et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89(24):12180-4.

12. Sasagawa T, Pushko P, Steers G et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995; 206(1):126-35.

13. Dupuy C, Buzoni-Gatel D, Touze A et al. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999; 73(11):9063-71.

14. Zhang LE, Zhou J, Chen S et al. HPV6b virus-like particles are potent immunogens without adjuvant in man. Vaccine 2000; 18(11-12):1051-8.

15. Koutsy LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347(21):1645-51.

16. Evans TG, Bonnez W, Rose RC et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183(10):1485-93.

17. Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93(4):284-92.

18. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23(17-18):2388-94.

19. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364(9447):1757-65.

20. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367(9518):1247-55.

21. Lopez de Turist JA, Cortes E, Martinez C et al. Recombinant vaccine for canine parvovirus in dogs. J Virol 1992; 66(5):2748-53.

22. Martinez C, Dalsgaard K, Lopez de Turis JA et al. Production of porcine parvovirus empty capsids with high immunogenic activity. Vaccine 1992; 10(10):684-90.

23. Antonis AF, Bruschke CJ, Rueda P et al. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 2006; 24(26):5481-90.

24. Ball JM, Hardy ME, Atmar RL et al. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 1998; 72(2):1345-53.

25. Guerrero RA, Ball JM, Krater SS et al. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fetal and vaginal) immune responses. J Virol 2001; 75(20):9713-22.

26. Tacket CO, Szeint M, Losonsky GA et al. Humoral, mucosal and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108(3):241-7.
28. Li TC, Yamakawa Y, Suzuki K et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 1997; 71(10):7207-13.
29. Li T, Takeda N, Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 2001; 19(25-26):3476-84.
30. Li TC, Suzuki Y, Ami Y et al. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine 2004; 22(3-4):370-7.
31. Goldmann C, Petry H, Frye S et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol 1999; 73(5):4465-9.
32. Caparros-Wanderley W, Clark B, Griffin BE. Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles. Vaccine 2004; 22(3-4):352-61.
33. Brautigam S, Sniezhkov E, Bishop DH. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3 and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 1993; 192(2):229-33.
34. Kibenge FS, Qian B, Nagy E et al. Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells. Can J Vet Res 1999; 63(1):49-55.
35. French T, Roy P. Synthesis of bluetongue virus (BTV) core-like particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J Virol 1990; 64(4):1530-6.
36. Belyaev AS, Hails RS, Roy P. High-level expression of five foreign genes by a single recombinant baculovirus. Gene 1995; 156(2):229-33.
37. Belyaev AS, Roy P. Development of baculovirus triple and quadruple expression vectors: coexpression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Research 1993; 21(5):1219-23.
38. Roy P. Orbiviruses. In: Knipe DM, Howley PM, eds. Fields' Virology, Fourth Edition. Philadelphia: Lippincott Williams and Wilkins, 2001:1835-1869.
39. Roy P, French T, Erasmus BJ. Protective efficacy of virus-like particles for bluetongue disease. Vaccine 1992; 10(1):28-32.
40. Roy P, Bishop DH, LeBlois H et al. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 1994; 12(9):805-11.
41. Roy P, Urakawa T, Van Dijk AA et al. Recombinant virus vaccine for bluetongue disease in sheep. J Virol 1990; 64(5):1998-2003.
42. Sabara M, Parker M, Aha P et al. Assembly of double-shelled rotavirus-like particles by simultaneous expression of recombinant VP6 and VP7 proteins. J Virol 1991; 65(12):6994-7.
43. Jiang B, Estes MK, Barone C et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 1999; 17(7-8):1005-13.
44. Madore HP, Estes MK, Zarley CD et al. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine 1999; 17(19):2461-71.
45. Kim Y, Nielsen PR, Hodgins D et al. Lactogenic antibody responses in cows vaccinated with recombinant bovine rotavirus-like particles (VLPs) of two serotypes or inactivated bovine rotavirus vaccines. Vaccine 2002; 20(7-8):1248-58.
46. Nguyen TV, Yuan L, MS PA et al. Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine. Vaccine 2006; 24(13):2302-16.
47. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE et al. Immunogenicity and protective efficacy of rotavirus 2/6 virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 2003; 21(25-26):3885-900.
48. Perez N, Pourgeux C, Mohamed A et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 2006; 80(4):1752-61.
49. Agnello D, Herve CA, Lavaux A et al. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an anti-rotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J Virol 2006; 80(8):3823-32.
50. Yamschikov GV, Ritter GD, Vey M et al. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology 1995; 214(1):50-8.
51. Baumeier TF, Ito S, Wong DT et al. Hepatitis C virus structural proteins assemble into virus-like particles in insect cells. J Virol 1998; 72(5):3827-36.
52. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001; 75(13):6154-65.
53. Jeong SH, Qiao M, Nascimbeni M et al. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004; 78(13):6995-7003.
54. Mortola E, Roy P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett 2004; 576(1-2):174-8.
55. Ho Y, Lin PH, Liu CY et al. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Commun 2004; 318(4):833-8.
56. Yao Q, Kuhlmann FM, Elser R et al. Production and characterization of simian—human immunodeficiency virus-like particles. AIDS Res Hum Retroviruses 2000; 16(3):227-36.
57. Wagner R, Deml L, Nortka F et al. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Interivirology 1996; 39(1-2):93-103.
58. Yao Q, Vuong V, Li M et al. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immune responses. Vaccine 2002; 20(19-20):2537-45.
59. Lechmann M, Murata K, Satô J et al. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 2001; 34(2):417-23.
60. Galanaz JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005; 18(1):244-51.
61. Pushko P, Tumpey TM, Bu F et al. Influenza virus-like particles comprised of the HA, NA and M1 proteins of H9N2 influenza virus induce protective immune responses in mice. Vaccine 2005; 23(50):5751-9.
62. Garcea RL, Gissmann L. Virus-like particles as vaccines and vectors for the delivery of small molecules. Curr Opin Biotechnol 2004; 15(6):513-7.
63. Beyer T, Herrmann M, Reiser C et al. Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation. Curr Drug Targets Infect Disord 2001; 1(3):287-302.
64. Faursch UC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res 2003; 63(13):3478-82.
65. Sedlik C, Saron M, Sarraseca J et al. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T-cells. Proc Natl Acad Sci USA 1997; 94(14):7503-8.
66. Faursch UC, Da Silva, DM, Kast WM. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. Vaccine 2005; 23(14):1720-9.
67. Lo-Man R, Rueda P, Sedlik C et al. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 1998; 28(4):1401-7.
68. Charpilletz E, Nejmeddine M BM, Parez N, Neumann E, Hewat E, Trugman G, Cohen J. Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells. J Biol Chem 2001; 276(31):29361-29367.
69. Ghosh MK, Deriaud E, Saron MF et al. Induction of protective anti-viral cytotoxic T-cells by a tubular structure capable of carrying large foreign sequences. Vaccine 2002; 20(9-10):1369-77.
70. Ghosh MK, Borca MV, Roy P. Virus-derived tubular structure displaying foreign sequences on the surface elicit CD4 + Th cell and protective humoral responses. Virology 2002; 302(2):383-92.
71. Larke N, Murphy A, Wirblich C et al. Induction of human immunodeficiency virus type 1-specific T-cells by a bluetongue virus tubule-vectorized vaccine prime-recombinant modified virus Ankara boost regimen. J Virol 2005; 79(14):14822-33.
72. Lindenburg CE, Stolte I, Langendam MW et al. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 2002; 20(17-18):2343-7.
73. Kirkner R, Taub J, Greenstone H et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67(12):6929-36.
74. Jiang X, Wang M, Graham DY et al. Expression, self-assembly and anti-genicity of the Norwalk virus capsid protein. J Virol 1992; 66(11):6527-32.
75. Laurent S, Vautherot JF, Madelaine MF et al. Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection. J Virol 1994; 68(10):6794-8.
76. Pletneva MA, Sosnovske SV, Sosnovske VA et al. Characterization of a recombinant human calicivirus capsid protein expressed in mammalian cells. Virus Res 1998; 55(2):129-41.
77. Hale AD, Crawford SE, Cialet M et al. Expression and self-assembly of Grimsby virus; anti-genic distinction from Norwalk and Mexico viruses. Clin Diagn Lab Immunol 1999; 6(1):142-5.
78. Belliot G, Noel JS, Li JF et al. Characterization of capsid genes, expressed in the baculovirus system, of three new genetically distinct strains of "Norwalk-like viruses." J Clin Microbiol 2001; 39(12):4288-95.
79. Brown CS, Van Lent JW, Vlak JM et al. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J Virol 1991; 65(5):2702-6.
80. Christensen J, Alexandersen S, Bloch B et al. Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink. J Gen Virol 1994; 75(Pt 1):149-55.
81. Hoque M, Shimizu N, Ishizu K et al. Chimeric virus-like particle formation of adeno-associated virus. Biochem Biophys Res Commun 1999; 266(2):371-6.
82. Koch G, van Roozelaar DJ, Verschueren CA et al. Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus. Vaccine 1995; 13(8):763-70.
83. Noteborn MH, Verschueren CA, Koch G et al. Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specific neutralizing epitope. J Gen Virol 1998; 79(Pt 12):3073-7.
84. Albina E, Truong C, Huter E et al. An experimental model for post-weaning multisystemic wasting syndrome (PMWS) in growing piglets. J Comp Pathol 2001; 125(4):292-303.
85. Kim Y, Kim J, Kang K et al. Characterization of the recombinant proteins of porcine circovirus type2 field isolate expressed in the baculovirus system. J Vet Sci 2002; 3(1):19-23.
86. Kosukegawa A, Arisaka F, Takayama M et al. Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells. Biochim Biophys Acta 1996; 1290(1):37-45.
87. Chang D, Fung CY, Ou WC et al. Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J Gen Virol 1997; 78(Pt 6):1435-9.
88. Brautigam S, Snezhkov E, Bishop DH. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VPO, VP3 and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 1993; 192(2):512-24.
89. Crawford SE, Labbe M, Cohen J et al. Characterization of virus-like particles produced by the expression of rosvirus capsid proteins in insect cells. J Virol 1994; 68(9):5945-22.
90. Overton HA, Fujii Y, Price IR et al. The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system. Virology 1989; 170(1):107-116.
91. Rasmussen L, Battles JK, Ennis WH et al. Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus. Virology 1990; 178(2):435-51.
92. Morikawa S, Booth TF, Bishop DH. Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors. Virology 1991; 185(1):288-97.
93. Thomsen DR, Meyer AL, Post LE. Expression of feline leukemia virus gp85 and gag proteins and assembly into virus-like particles using the baculovirus expression vector system. J Gen Virol 1992; 73(Pt 7):1819-24.
94. Rafnar B, Töbin GJ, Nagashima K et al. Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells. Virus Res 1998; 53(2):107-20.
95. Kakker N, MikhaiLO M, Nermut MV et al. Bovine leukemia virus Gag particle assembly in insect cells: Formation of chimeric proteins by domain-switched leukemia/ lentivirus Gag polyprotein. Virology 1999; 265(2):303-318.
96. Johnson MC, Scobie HM, Vogt VM. PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells. J Virol 2001; 75(9):4407-12.
97. Nagy E, Huber P, Krell PJ et al. Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV. J Gen Virol 1991; 72(Pt 3):753-6.
98. Betenbaugh M, Yu M, Kuehl K et al. Nucleocapsid-and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. Virus Res 1995; 38(2-3):111-24.
99. Fernandez-Arias A, Risco C, Martinez S et al. Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles. J Gen Virol 1998; 79(Pt 5):1047-54.
100. Martinez-Tortorellada JL, Saubi N, Pages-Mante A et al. Structuredependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines. Vaccine 2003; 21(23):3342-50.